Arcutis Biotherapeutics, Inc. ARQT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $43.22M-39.9% | $71.95M-19.4% | $89.32M+62.8% | $54.88M-44.0% | ||
| $178.08M+13.7% | $156.62M-14.6% | $183.46M-48.5% | $355.95M+22.5% | ||
| $308K-50.1% | $617K-33.3% | $925K-25.0% | $1.23M-20.0% | ||
| $453.45M+112% | $213.75M+184% | $75.2M+591% | $10.89M— | ||
| $77.99M+40.1% | $55.67M+20.8% | $46.07M+108% | $22.11M— | ||
| $5.05M+17.4% | $4.3M-56.8% | $9.95M+75.8% | $5.66M— | ||
| $5.03M+762% | $584K+20.2% | $486K+23.0% | $395K— | ||
| $12.55M+30.2% | $9.64M+258% | $2.7M+84.7% | $1.46M— | ||
| $82.96M+26.7% | $65.49M+3.1% | $63.5M+30.9% | $48.5M-23.4% | ||
| $138.4M— | —— | —— | —— | ||
| $411.23M+22.5% | $335.82M+1.6% | $330.43M-24.5% | $437.41M+8.6% | ||
| $1.04M+0.2% | $1.04M-32.4% | $1.54M-18.2% | $1.88M-16.8% | ||
| $4.47M+129% | $1.95M-17.3% | $2.36M-13.2% | $2.72M-10.5% | ||
| $14.81M+56.3% | $9.48M+47.2% | $6.44M-10.4% | $7.19M— | ||
| $1.42M+138% | $596K0.0% | $596K+664% | $78K0.0% | ||
| $39.68M— | —— | —— | —— | ||
| $432.97M+24.1% | $348.89M+2.2% | $341.37M-24.0% | $449.27M+10.1% | ||
| $57.93M+6.4% | $54.46M-0.6% | $54.81M+42.8% | $38.4M+113% | ||
| $20.53M-69.3% | $66.79M+96.8% | $33.94M+19.8% | $28.32M+10.9% | ||
| $1M— | $0— | $0— | —— | ||
| $129.84M+60.3% | $81.01M+73.6% | $46.67M+23.4% | $37.81M+13.4% | ||
| $107.96M+0.7% | $107.2M-46.9% | $201.8M+2.0% | $197.77M+173% | ||
| $5.27M+106% | $2.56M-24.2% | $3.38M-17.9% | $4.12M-13.8% | ||
| $431K-24.4% | $570K-32.9% | $849K— | $0-100% | ||
| $243.49M+27.3% | $191.35M-24.3% | $252.7M+5.4% | $239.69M+117% | ||
| 300M+2,499,900% | 12K+33.3% | 9K+50.0% | 6K+20.0% | ||
| $1.33B+3.8% | $1.28B+19.5% | $1.07B+15.1% | $930.43M+31.7% | ||
| -$1.14B-1.4% | -$1.12B-14.3% | -$981.9M-36.4% | -$719.76M-76.3% | ||
| -$44K-529% | -$7K-275% | $4K+100% | -$1.09M-326% | ||
| $189.48M+20.3% | $157.54M+77.7% | $88.67M-57.7% | $209.58M-29.6% | ||
| $432.97M+24.1% | $348.89M+2.2% | $341.37M-24.0% | $449.27M+10.1% | ||
| $138.28M-11.5% | $156.3M-14.8% | $183.37M-48.6% | $357.03M+22.7% | ||
| $138.28M— | —— | —— | —— | ||
| $178.08M+13.7% | $156.62M-14.6% | $183.46M-48.5% | $355.95M+22.5% | ||
| $178.08M+13.7% | $156.62M-14.6% | $183.46M-48.5% | $355.95M+22.5% | ||
| $12.55M+30.2% | $9.64M+258% | $2.7M+84.7% | $1.46M— | ||
| $39.68M— | —— | —— | —— | ||
| $1.42M+138% | $596K0.0% | $596K+664% | $78K0.0% | ||
| $177.96M+13.9% | $156.3M-14.8% | $183.37M-48.6% | $357.03M+22.7% | ||
| $4.47M+129% | $1.95M-17.3% | $2.36M-13.2% | $2.72M-10.5% | ||
| $14.81M+56.3% | $9.48M+47.2% | $6.44M-10.4% | $7.19M— | ||
| $4.47M+129% | $1.95M-17.3% | $2.36M-13.2% | $2.72M-10.5% | ||
| $1.42M+138% | $596K0.0% | $596K+664% | $78K0.0% | ||
| $4.47M+129% | $1.95M-17.3% | $2.36M-13.2% | $2.72M-10.5% | ||
| $1.42M+138% | $596K0.0% | $596K+664% | $78K0.0% | ||
| $20.53M-1.0% | $20.75M+39.5% | $14.87M+6.2% | $14M+53.3% | ||
| $116.31M+74.1% | $66.79M+96.8% | $33.94M+19.8% | $28.32M+10.9% | ||
| $116.31M+74.1% | $66.79M+96.8% | $33.94M+19.8% | $28.32M+10.9% | ||
| $20.53M-1.0% | $20.75M+39.5% | $14.87M+6.2% | $14M+53.3% | ||
| —— | —— | —— | —— | ||
| $865K-22.8% | $1.12M-63.6% | $3.08M-25.0% | $4.1M+54.8% | ||
| $114.52M+3.6% | $110.59M-46.3% | $205.92M+1.7% | $202.54M+161% | ||
| $100M0.0% | $100M-50.0% | $200M0.0% | $200M+167% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| —— | —— | —— | —— | ||
| 123.3M+4.7% | 117.8M+21.8% | 96.8M+58.5% | 61.1M+21.3% | ||
| $127.95M+197% | $43.12M+2,905% | $1.44M-92.3% | $18.67M-46.5% | ||
| —— | 10M0.0% | 10M0.0% | 10M0.0% | ||
| —— | 0— | 0— | 0— | ||
| $12K0.0% | $12K+33.3% | $9K+50.0% | $6K+20.0% | ||
| —— | —— | —— | —— | ||
| 6.4M+20.5% | 5.3M-32.5% | 7.9M+5.9% | 7.5M+29.8% | ||
| $134K-58.0% | $319K+149% | $128K+1,729% | $7K— | ||
| $21K— | $0-100% | $30K-97.3% | $1.09M+329% | ||
| $9.17+37.1% | $6.69-63.9% | $18.52-7.1% | $19.93+4.6% | ||
| $177.96M+13.9% | $156.3M-14.8% | $183.37M-48.6% | $357.03M+22.7% | ||
| $78.31M+104% | $38.43M+232% | $11.58M— | —— | ||
| $0— | —— | —— | —— | ||
| $21K— | $0-100% | $30K-97.3% | $1.09M+329% | ||
| $134K-58.0% | $319K+149% | $128K+1,729% | $7K— | ||
| $177.96M+13.9% | $156.3M-14.8% | $183.37M-48.6% | $357.03M+22.7% | ||
| $39.68M— | —— | —— | —— | ||
| $39.68M— | —— | —— | —— | ||
| $138.28M— | —— | —— | —— | ||
| $138.4M— | —— | —— | —— | ||
| $178.08M+13.7% | $156.62M-14.6% | $183.46M-48.5% | $355.95M+22.5% | ||
| —— | —— | —— | —— | ||
| $0— | $0-100% | $3K— | —— | ||
| $0— | $0— | $0— | —— | ||
| $221.3M-3.2% | $228.6M-16.2% | $272.8M-33.6% | $410.8M+5.7% | ||
| $425K— | $0-100% | $4.19M-46.9% | $7.9M-40.3% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | ||
| $300M0.0% | $300M0.0% | $300M0.0% | $300M0.0% | ||
| $123.33M+4.7% | $117.85M+21.8% | $96.79M+58.5% | $61.05M+21.3% | ||
| $123.33M+4.7% | $117.85M+21.8% | $96.79M+58.6% | $61.04M+21.5% | ||
| $8.82M+20.5% | $7.32M+50.2% | $4.88M+161% | $1.87M— | ||
| $1M0.0% | $1M— | —— | —— | ||
| $100M0.0% | $100M-50.0% | $200M0.0% | $200M+167% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $17.04M+124% | $7.62M+131% | $3.3M-32.1% | $4.86M+52.2% | ||
| —— | $10M0.0% | $10M0.0% | $10M0.0% | ||
| —— | $0— | $0— | $0— | ||
| $2.58M-20.6% | $3.24M+217% | $1.02M+495% | $172K-96.9% | ||
| $9.49M+28.7% | $7.37M-14.4% | $8.61M— | —— | ||
| —— | —— | —— | —— | ||
| $6.44M+20.5% | $5.34M-32.5% | $7.92M+5.9% | $7.48M+29.8% | ||
| $9.17+37.1% | $6.69-63.9% | $18.52-7.1% | $19.93+4.6% | ||
| $127.95M+197% | $43.12M+2,905% | $1.44M-92.3% | $18.67M-46.5% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcutis Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 2.68 — current assets exceed current liabilities.
- Where does Arcutis Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.